Lanean...
Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...
Gorde:
| Argitaratua izan da: | BMC Med |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490602/ https://ncbi.nlm.nih.gov/pubmed/26137986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0398-0 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|